

HPV

赵爽¹ 赵雪莲¹ 胡尚英¹ 王岩¹ 热米拉·热扎克¹ 徐小倩¹ 段仙芝² 陈凤¹
张询³ 赵方辉¹

¹国 /国 100021² /国 100176³ /国 100021

赵方辉 Email zhaofangh@cicams.ac.cn

【摘要】 目的

方法 2017 6 托克旗3个农村地 开展以
基础 多 心 共纳入 对象9 517名 所有 对象均通过 采样方
法采集2份 阴道 泌 careHPV PCR HPV 对
基 PCR方法 HPV 方法 阴道 阴道 有
阴道
结果 HPV 1 842 21.83% HPV 269 24.93% 个
HPV 有 $\chi^2=5.328 P=0.021$ 样 1
2.83% 30/1 059 0.87% 73/8 378 有 $\chi^2=33.509 P<$
0.001 样 2 以 1.04% 11/1 059 ,
0.95% 80/8 378 $\chi^2=0.069 P=0.793$ 样 2 以
HR-HPV 均 HPV16 52 58 多
41.37% 44.35% $\chi^2=0.764 P=0.382$ 结论 HPV
对 时 应 对 HPV16 52 58

视

【关键词】 基因

基金项目:美 医 基 会卫生政 与体系科 公开竞 项目 16-255 , 医 科
院医 与健康科技创新工程项目 2016-I2M-1-019 2017-I2M-1-002

DOI 10.3760/cma.j.issn.0254-6450.2019.11.018

Comparison of high-risk human papillomavirus infection rate and genotype distribution between Han and Mongolian women

Zhao Shuang¹, Zhao Xuelian¹, Hu Shangying¹, Wang Yan¹, Remila Rezhake¹, Xu Xiaolian¹, Duan Xianzhi², Chen Feng¹, Zhang Xun³, Zhao Fanghui¹

¹Department of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; ²Department of Gynecology and Obstetrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100176, China; ³Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Corresponding author: Zhao Fanghui, Email: zhaofangh@cicams.ac.cn

【Abstract】 Objective

Methods In June 2017, a multicenter, population-based study for cervical cancer screening in low-resource settings in China was conducted in three rural areas: Xiangyuan and Yangcheng counties in Shanxi province, and Etuoke county in Inner Mongolia Autonomous Region. A total of 9 517 women aged 30–65 years were included in the study, and two cervical and vaginal secretion samples were collected from them for HPV and PCR-based HPV DNA tests. The positive samples in any of two tests were used for PCR-based HPV genotyping test by using Sansure-pioneered One-Step Fast Release technology. Women with positive results in any the HPV tests were referred for colposcopy and punch biopsy was given if cervical intraepithelial neoplasia lesion (low-grade lesion or worse) was suspected in colposcopy evaluation. Endocervical curettage was performed if women had an unsatisfactory colposcopy exam (the squamocolumnar junction was not completely visible). Pathological detection result was used as the golden standard of diagnosis. **Results** HR-HPV infection rates in Han and Mongolian women were 21.83% (1 842/8 438) and 24.93% (269/1 079), respectively. There were statistical differences in HPV infection rates between the two ethnic groups ($\chi^2=5.328, P=0.021$). The detection rate of cervical intraepithelial neoplasia grade 1 in Mongolian women (2.83%) was higher than that in Han women (0.87%), and the difference was statistically significant ($\chi^2=33.509, P<0.001$). There were no significant differences in cervical intraepithelial neoplasia grade 2 or worse detection rate between the two ethnic groups Mongolian woman: 1.04% (11/1 059), Han Woman: 0.95% (80/8 378), $\chi^2=0.069, P=0.793$. Among Han and Mongolian women with cervical intraepithelial neoplasia grade 2 or worse, the three most common HR-HPV types were HPV16, HPV52 and HPV58. There was no significant difference for multiple infection rate between Han and Mongolian women (41.37% vs. 44.35%, $\chi^2=0.764, P=0.382$). **Conclusions** The results show that HPV infection rate in Mongolian women was higher than that in Han women. Close attention should be paid to HPV16, 52 and 58 in the prevention and control of cervical cancer in Han and Mongolian women.

【Key words】 Human papillomavirus; Genotype

Fund programs: Open Competition Program in the Field of Health Policy and Systems Sciences from China Medical Board (16–255); Chinese Academy of Medical Science Initiative for Innovative Medicine (2016–I2M–1–019, 2017–I2M–1–002)

DOI:10.3760/cma.j.issn.0254–6450.2019.11.018

本 本 国

high risk-human
careHPV PCR HPV
HPV 本 基于 PCR HPV
HPV HPV

1-3

HPV
HPV 少 基于此 本 3. ..
比 我国汉 我国 HPV 1 careHPV 国 Qiagen ..
我国 hybrid capture 2 HC2
基于 HC2 本 HR-HPV DNA
RNA DNA : RNA
DNA : RNA
DNA : RNA

对象与方法

1. 2017 6 国
/国 WHO/
IARC 基 DNA : RNA 偶 通 信号
基 我 大 化 光 14 种 HR-HPV
国 被 DNA : RNA 偶 通 信号
3 9 517 30 65 68 但 能单独 本 出
HPV DNA ≥ 1.0 pg/ml 即

2. .. 限 国械注 20163401304
基 2 PCR HPV 该 步 快速

HPV DNA ≥ 1.0 pg/ml 即
2 PCR HPV 湖南圣湘 限
15种HR-HPV核 试剂盒 湖南圣湘
限 国械注 20163401304
该 步 快速

careHPV		PCR HPV	
HR-HPV	HPV16 18 31 33 35 39 45 51 52	PCR	HPV
53 56 58 59 66 68	≤39	20163401295	同 以
HR-HPV			
careHPV	PCR HPV		
PCR	HPV		
PCR HPV			

变	征	
	(n=8 438)	(n=1 079)
龄 岁 $M(P_{25} \sim P_{75})$	47(42 ~ 53)	48(43 ~ 53)
经初潮 龄 岁 $M(P_{25} \sim P_{75})$	15(14 ~ 16)	16(14 ~ 17)
初次 龄 岁 $M(P_{25} \sim P_{75})$	22(21 ~ 23)	21(20 ~ 23)
经 龄 岁 $M(P_{25} \sim P_{75})$	50(48 ~ 52)	49(47 ~ 52)
文化程度 (%)		
以下	26.89(2 267/8 431)	54.31(586/1 079)
初 以上	73.11(6 164/8 431)	45.69(493/1 079)
3 (%)		
<2	98.58(8 313/8 433)	98.60(1 059/1 074)
≥2	1.42(120/8 433)	1.40(15/1 074)

上 15 HR-HPV
 4. 疾 确 诊: 结 果 作 最 终 疾 诊 断 金
 均 由 医 院 肿 瘤 医 院 专 家 盲
 下 读 片 或 质 控 宫 颈 管 上 皮 瘤 变 命 名
 系 统 记 录 诊 断 结 果 正 常 宫 颈 上 皮 瘤 样 变
 1 级 cervical intraepithelial neoplasia grade 1 CIN1
 宫 颈 上 皮 瘤 样 变 2 级 cervical intraepithelial
 neoplasia grade 2 CIN2 宫 颈 上 皮 瘤 样 变 3 级
 cervical intraepithelial neoplasia grade 3 CIN3 宫
 颈 癌 如 未 达 到 正 常 宫 颈 上 皮 瘤 样 变 结 果

0.021 HPV52 4.21% 最 常
 HR-HPV 19.27% 次
 HPV58 3.42% 16 3.09% 53 2.96% 68 2.69%
 51 2.39% 最 常 HR-HPV
 HPV58 3.34% 68 3.34% 52 3.15% 16
 2.78% 56 2.50% 53 2.32% 以 下
 感 染 : HPV18 0.96% vs.
 1.85% $\chi^2=7.276 P=0.007$ HPV31 1.27% vs.
 2.04% $\chi^2=4.251 P=0.039$ HPV35 0.65% vs.
 1.58% $\chi^2=10.872 P=0.001$ HPV45 0.46% vs.
 0.93% $\chi^2=4.031 P=0.045$ 表 2

PCR 结 果 均 HPV
 变 4-5
 5. 统 :
 以 % 表 示
 两 民 龄 服 从 正 态 布 故 以 $M P_{25} \sim$
 P_{75} 描 述 同 民 HPV 感 染 同 变
 出 χ^2 或 Fisher exact 验 所 统
 通 过 SPSS 23.0 软 件 完 成 以 $P < 0.05$ 差 异
 统 义 所 验 均 双 侧 验

HPV 感 染 31 ~ 45 岁 HPV 感 染 上
 46 岁
 50 岁
 55 岁 过 同 龄
 HPV 感 染 2
 差 $\chi^2=4.585 P=0.032$ 表 3
 29.50% 36.89% 两 差 异 统 义

结 果
 1. 征:共 纳 入 8 438 1 079
 龄 $M P_{25} \sim P_{75}$ 47
 42 ~ 53 岁 48 43 ~ 53 岁 经 初 潮 龄
 15 14 ~ 16 岁 16 14 ~ 17 岁 初 次 龄
 22 21 ~ 23 岁 21 20 ~ 23 岁 73.11%
 6 164/8 431 文 化 程 初 以 上
 45.69% 493/1 079 差 异 统
 $\chi^2=342.497 P < 0.001$
 征 表 1

3. 宫 颈 变 出 HR-HPV 布:
 CIN1 CIN2+ 出 0.87%
 73/8 378 0.95% 80/8 378
 2.83% 30/1 059 1.04% 11/1 059 两 民 CIN1
 出 差 异 统 义 $\chi^2=33.509 P <$
 0.001 CIN2+ 出 差 异 统 义 $\chi^2=$
 0.069 $P=0.793$ 表 3
 宫 颈 变 HPV16 感 染
 所 均 最 58.82% vs. 34.14%
 CIN1 变 HR-HPV 布 6 次
 HPV16 58 51 52 68 56 次

2. HPV 感 染 : HPV 感 染
 21.83% 1 842/8 438 24.93% 269/
 1 079 两 民 差 异 统 义 $\chi^2=5.328 P=$

HPV16 56 58 18 51 52 68 HPV16 感 染 所
 差 异 统 义 $\chi^2=4.162 P=0.041$
 两 民 CIN2+ HR-HPV 布 3



HPV16 , 内其他 报道 完全一致: 一些 、 ,HPV16 HR-HPV基 [12-14] 而,也有 、 ,江苏 广东 浙江省 HPV52 流行超过 HPV16^[15-17] 以上 表明 HPV 存 地区 、 尽管 同 HPV16 顺 自 人群中存 ,但 有宫颈病 人群中 HPV16 首 HPV16 致癌力 强,故其 有宫颈病 人群中所占 例、 HPV52 58 CIN2+ 中 排 HPV16之后 , 其他 中东 亚CIN2 一致^[18-19] , 制 针对中 HPV预防 疫苗 ,除 宫颈癌 关 HPV16 18 外,还应提 对HPV52 58 视度,进而提 人群 HPV免疫效 ,从而预防宫颈癌 发生。

汉 HR-HPV 病 40.14% vs. 46.11%, $\chi^2=2.361, P=0.124$ CIN1 50.00% vs. 46.43%, $\chi^2=0.102, P=0.749$ CIN2+ 48.10% vs. 27.27%, $\chi^2=1.689, P=0.194$ 中 学

讨 论

汉 HPV 中汉 学,薛 [21] 同样、 宫颈癌患 中 学 样 HPV HR-HPV HPV52 58 16 53 68 51 但 CIN2+ 样 HR-HPV HPV58 68 52 样 HPV 16 56 53 3 HR-HPV HPV16 52 58 样 HPV 中 HPV 样 样 reHPV PCR HPV 样 样

段仙芝等^[20] 、 , CIN1 CIN2+ 2.87% 1.80%, CIN1 近,CIN2+ 样 HPV 中汉 学,薛 [21] 同样、 宫颈癌患 中 学 样 HPV HR-HPV HPV52 58 16 53 68 51 但 CIN2+ 样 HR-HPV HPV58 68 52 样 HPV 16 56 53 3 HR-HPV HPV16 52 58 样 HPV 中 HPV 样 样 reHPV PCR HPV 样 样 内外关 宫颈癌发生 ee等^[22] , 发生宫 明等^[23] 同样发现 宫颈病 度 ,HPV 有 且 宫颈病 明 HPV 汉 村

HR-HPV 患病 [8] HPV 汉 内其他 报道一致^[9] 中 来自内 自治区鄂托克旗,该地区地 域辽阔,人口 散,且 数 生活 边远牧区, 距离医疗机构远,医疗卫生服务可 基 中 人群 17个荟萃 析 、 , HPV 呈现双峰现象,农村 双峰 15~24岁 45~49岁^[8] 外 同样 、 , 45~50岁 围绝经期会 现HPV 第二 峰^[10-11] 基 一致,但由 <30岁年龄组 样 量 少,故小年龄组 HPV 峰 明 进一步 析发现 年龄 50岁 之后开始上升,且 汉 上升更 ,

自 人群中 HPV52

HPV HPV52 58
 16 HR-HPV HPV58
 68 52
 CIN2+ HR-HPV 3
 HPV16 52 58
 HPV16 52 58

利益冲突

参 考 文 献

1 de Snøe S, Gillies E. Global prevalence and incidence of cervical human papillomavirus infection in women: a systematic review. *Lancet Infect Dis* 2007; 7(12): 453-459. I 10.1016/S1473-3099(07)0158-5.

2 Triller-Vandeviver J, Sherrin E. Human papillomavirus in men: a review of the literature. *Sex Transm Infect* 1999; 73(3): 206-211. I 10.1046/j.1525-1438.1999.99020.

3 Nioli E, Nardelli J, Rinaldi E. Human papillomavirus infection and cervical cancer: a review. *Int J Gynecol Cancer* 2011; 21(4): 428-433. I 10.1016/j.igcc.2011.06.032.

4 Elrom Melov V, Johnson E. The epidemiology of HPV infection: a review. *Sex Transm Infect* 2014; 88(3): 130-133. I 10.1136/bmj-2013-028130.

5 Wang H, Shen H. Risk factors for cervical cancer: a review. *Chin J Cancer* 2010; 49(12): 45-51. I 10.1158/1940-6220.2010.028130.

6 Wang H, Shen H. High-risk human papillomavirus infection and cervical cancer: a review. *Chin J Cancer* 2010; 49(12): 45-51. I 10.1158/1940-6220.2010.028130.

7 Wang H, Shen H. Role of human papillomavirus infection in cervical cancer: a review. *Chin J Cancer* 2019; 58(2): 215-222. I 10.1093/cjco/ckz050.

8 Wang H, Shen H. Human papillomavirus infection and cervical cancer: a review. *Chin J Cancer* 2012; 51(12): 2929-2938. I 10.1002/cjco.12511.

9 Wang H, Ji P. Prevalence of human papillomavirus infection in women in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2018; 57(1): 148-156. I 10.1002/cjco.12488.

10 Glez H, Hernandez R. Prevalence of human papillomavirus infection and cervical cancer: a review. *Chin J Cancer* 2005; 44(11): 1808-1816. I 10.1086/42819.

11 Carrioni P, Perlo G. Prevalence of human papillomavirus infection in women: a review. *Chin J Cancer* 2005; 44(5): 141-145. I 10.1186/1475-2875-44-5.

12 Wang H, Shen H. Human papillomavirus infection in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2006; 45(11): 1593-1599. I 10.1038/nrj.2006.3450.

13 Wang H, Shen H. Human papillomavirus infection in women in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2009; 48(11): 1635-1640. I 10.1038/nrj.2009.351.

in women in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2009; 48(11): 1635-1640. I 10.1038/nrj.2009.351.

14 Wang H, Shen H. Human papillomavirus infection in women in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2009; 48(11): 1635-1640. I 10.1038/nrj.2009.351.

15 Wang H, Shen H. Cervical prevalence and incidence of human papillomavirus infection in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2014; 53(11): 2604-2611. I 10.1002/cjco.12896.

16 Wang H, Shen H. Prevalence and incidence of HPV infection in China: a cross-sectional study. *Chin J Cancer* 2016; 55(9): 103-104. I 10.1002/cjco.12491.

17 Wang H, Shen H. Prevalence and incidence of HPV infection in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2010; 49(6): 43-44. I 10.1186/1475-2875-49-66.

18 Wang H, Shen H. Cervical prevalence and incidence of human papillomavirus infection in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2014; 53(9): 5-6. I 10.1186/1475-2875-53-53.

19 Wang H, Shen H. Human papillomavirus infection and cervical cancer: a review. *Epidemiol Infect* 2008; 136(10): 11-16. I 10.1017/S0950268808005064.

20 Wang H, Shen H. Human papillomavirus infection and cervical cancer: a review. *Epidemiol Infect* 2012; 140(13): 190-193. I 10.3969/j.issn.1122-8624.2012.03.010.

21 Wang H, Shen H. Human papillomavirus infection and cervical cancer: a review. *Epidemiol Infect* 2012; 140(13): 190-193. I 10.3969/j.issn.1122-8624.2012.03.010.

22 Wang H, Shen H. Multiple HPV infection in cervical cancer: a review. *Chin J Cancer* 2003; 42(18): 18-19. I 10.1016/S0304-3835(03)00312-4.

23 Wang H, Shen H. Multiple HPV infection in cervical cancer: a review. *Chin J Cancer* 2010; 49(16): 6-7. I 10.3969/j.issn.1122-8624.2010.01.022.

24 Wang H, Shen H. Cervical prevalence and incidence of human papillomavirus infection in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2010; 49(16): 6-7. I 10.3969/j.issn.1122-8624.2010.01.022.

25 Wang H, Shen H. Cervical prevalence and incidence of human papillomavirus infection in Henan Province, China: a cross-sectional study. *Chin J Cancer* 2011; 50(18): 1225-1229. I 10.1603/j.issn.1122-8624.2011.16.008.